{"id":574,"date":"2024-06-17T15:50:00","date_gmt":"2024-06-17T15:50:00","guid":{"rendered":"https:\/\/www.neolyspharma.ca\/member\/martin-tremblay\/"},"modified":"2024-08-23T10:49:33","modified_gmt":"2024-08-23T10:49:33","slug":"martin-tremblay","status":"publish","type":"member","link":"https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/","title":{"rendered":"Martin Tremblay"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"categories":[24,1],"class_list":["post-574","member","type-member","status-publish","hentry","category-advisory-committee","category-non-classifiee"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Martin Tremblay - Neolyspharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Martin Tremblay - Neolyspharma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/\" \/>\n<meta property=\"og:site_name\" content=\"Neolyspharma\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-23T10:49:33+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/martin-tremblay\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/martin-tremblay\\\/\",\"name\":\"Martin Tremblay - Neolyspharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\"},\"datePublished\":\"2024-06-17T15:50:00+00:00\",\"dateModified\":\"2024-08-23T10:49:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/martin-tremblay\\\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/martin-tremblay\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/martin-tremblay\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Martin Tremblay\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"name\":\"Neolys Pharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\"},\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\",\"name\":\"Neolys Pharma inc.\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"contentUrl\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"width\":512,\"height\":242,\"caption\":\"Neolys Pharma inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neolys-pharma\"],\"legalName\":\"Neolys Pharma inc.\",\"telephone\":\"+1-418-931-2195\",\"email\":\"info@neolyspharma.ca\",\"description\":\"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Martin Tremblay - Neolyspharma","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Martin Tremblay - Neolyspharma","og_url":"https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/","og_site_name":"Neolyspharma","article_modified_time":"2024-08-23T10:49:33+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/","url":"https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/","name":"Martin Tremblay - Neolyspharma","isPartOf":{"@id":"https:\/\/neolyspharma.ca\/en\/#website"},"datePublished":"2024-06-17T15:50:00+00:00","dateModified":"2024-08-23T10:49:33+00:00","breadcrumb":{"@id":"https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neolyspharma.ca\/en\/member\/martin-tremblay\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neolyspharma.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Martin Tremblay"}]},{"@type":"WebSite","@id":"https:\/\/neolyspharma.ca\/en\/#website","url":"https:\/\/neolyspharma.ca\/en\/","name":"Neolys Pharma","description":"","publisher":{"@id":"https:\/\/neolyspharma.ca\/en\/#organization"},"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/neolyspharma.ca\/en\/#organization","name":"Neolys Pharma inc.","url":"https:\/\/neolyspharma.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","contentUrl":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","width":512,"height":242,"caption":"Neolys Pharma inc."},"image":{"@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neolys-pharma"],"legalName":"Neolys Pharma inc.","telephone":"+1-418-931-2195","email":"info@neolyspharma.ca","description":"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers."}]}},"_links":{"self":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/member\/574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/member"}],"about":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/types\/member"}],"wp:attachment":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/media?parent=574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/categories?post=574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}